Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 7Completed 5Withdrawn 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 1Learning Disabilities 1Dyslexia 1

Interventions

pembrolizumab 436Carboplatin 321Nivolumab 287Cyclophosphamide 280Specimen Handling 257Cisplatin 251Paclitaxel 248Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 166atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 112Oxaliplatin 112Etoposide 111Radiosurgery 108Fluorouracil 108venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Lovastatin × Clear all
NCT02964884 2025-06-24

Interventions for Reading Disabilities in NF1

Vanderbilt University

Phase 2 Active not recruiting
120 enrolled
CNS

Dyslexia, Learning Disabilities, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡